Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Allouchery M, Lombard T, Martin M, the French Network of Regional Pharmacovigilance Centers, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020;8:e001622. doi: 10.1136/jitc-2020-001622

This paper has been updated since first published to revise affiliation 10 to ‘+Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France’.